Treatment with monoclonal antibodies (mAbs) and anticytokine biologics is not effective in decreasing the frequency of coronary artery aneurysms (CAAs) in patients with Kawasaki disease (KD), but the incidence of treatment resistance may be reduced with these agents compared with conventional intravenous immunoglobulin (IVIG) therapy alone, according to findings from...
Latest News
Use of a new diagnostic guideline for hypersensitivity pneumonitis (HP), published in 2020, has resulted in half of patients with HP also being diagnosed with idiopathic pulmonary fibrosis (IPF), according to authors of a recent study published in the American Journal of Respiratory and Critical Care Medicine. The investigators who conducted...
FREIENBACH, Switzerland – EffRx Pharmaceuticals SA, a commercial-stage company that commercializes niche and orphan medicines in Switzerland and Europe, today announced that Swissmedic has approved Bronchitol® (inhaled mannitol) for the treatment of cystic fibrosis (CF) in adults and in children aged 6 years and above as add‐on to other medicines. Bronchitol® is...
Stockholm, Sweden — Egetis Therapeutics AB (publ) (Nasdaq Stockholm: EGTX) announced that the Company, as part of its initiatives to increase disease awareness about MCT8 deficiency, has participated and informed about MCT8 deficiency, at the following medical conferences during the first quarter of 2023: British Paediatric Neurology Association (BPNA) Annual...
Stockholm, Sweden — Egetis Therapeutics AB (publ) (“Egetis” or the “Company”) (NASDAQ Stockholm: EGTX), today announced that its partner Fujimoto Pharmaceutical Corporation, which has an exclusive license agreement to develop and commercialize Emcitate® (tiratricol) for the treatment of MCT8 deficiency in Japan, has been granted Orphan Drug Designation (ODD) for tiratricol...
STOCKHOLM, Sweden – Egetis Therapeutics AB (publ) (“Egetis” or the “Company”) (STO:EGTX)(NASDAQ Stockholm:EGTX) today announced its participation in the annual conference of the International Society for Pharmacoeconomics and Outcomes Research, ISPOR 2026, taking place May 17 to 20, 2026, in Philadelphia, PA, USA. ISPOR is a leading global conference for health...
ASSIUT, Egypt – Seven previously unreported mutations linked to type 1 Gaucher disease were identified in a study analyzing the genetic code of dozens of people with the condition in Egypt. “All patients carrying these novel variants exhibited reduced enzyme levels and clinical symptoms characteristic of type 1 [Gaucher disease], without...
PALO ALTO, Calif. — Eiger BioPharmaceuticals, Inc, a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare metabolic diseases, today announced that it and its partner AnGes, Inc. received marketing approval from the Ministry of Health, Labour and Welfare for Zokinvy (lonafarnib), a treatment for Hutchinson-Gilford progeria...
Palo Alto, Calif. — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) and other serious diseases, reported financial results for fourth quarter and full year 2022 and provided a business update. “In December, we announced that both our...
DOVER, Del. — Eilean Therapeutics LLC, a biopharmaceutical company dedicated to discovering and developing best-in-class and first-in-class small molecule inhibitors to target escape mutations in hematologic and solid malignancies, today announced the completion of a single ascending dose Phase 1 clinical study of lomonitinib and initiation of a multiple ascending...